| NCT02570984 | Boston Children´s Hospital|National Institute of Allergy and Infectious Diseases (NIAID) | Asthma | 2018-11-27 | PHASE2 |
| NCT00180011 | DiMango, Emily, M.D.|Genentech, Inc.|Novartis | Asthma | 2005-09 | PHASE2|PHASE3 |
| NCT01430403 | National Institute of Allergy and Infectious Diseases (NIAID)|Inner-City Asthma Consortium | Asthma | 2011-09 | PHASE4 |
| NCT06228560 | Longbio Pharma | Chronic Spontaneous Urticaria | 2024-01-26 | PHASE2 |
| NCT02477332 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 2015-07-15 | PHASE2 |
| NCT00949078 | Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID) | Food Allergy|Peanut Allergy | 2009-07 | PHASE2 |
| NCT04943744 | Stanford University | Eosinophilic Disorder|Food Allergy | 2021-05-17 | EARLY_PHASE1 |
| NCT00267202 | Novartis|Genentech, Inc.|Tanox | Allergic Asthma | 2005-12 | PHASE4 |
| NCT00377572 | National Institute of Allergy and Infectious Diseases (NIAID)|Inner-City Asthma Consortium | Asthma | 2006-10 | PHASE4 |
| NCT01294878 | Fondazione IRCCS Policlinico San Matteo di Pavia | Interstitial Cystitis|Painful Bladder Syndrome | 2009-03 | PHASE3 |
| NCT02966314 | University of Wisconsin, Madison|Novartis Pharmaceuticals | Idiopathic Angioedema | 2017-03-30 | PHASE4 |
| NCT05053334 | Syneos Health|CuraTeQ Biologics Private Ltd. | Healthy Volunteers | 2022-02-16 | PHASE1 |
| NCT02329223 | Novartis Pharmaceuticals | Chronic Spontaneous Uriticaria | 2014-12 | PHASE3 |
| NCT04585997 | University of Newcastle, Australia|GlaxoSmithKline | Asthma|Eosinophilic Asthma | 2018-11-03 | PHASE4 |
| NCT01781637 | Boston Children´s Hospital|Children´s Hospital of Philadelphia|Stanford University|Ann & Robert H Lurie Children´s Hospital of Chicago | Peanut Allergy|Food Allergy | 2013-01 | PHASE1|PHASE2 |
| NCT00226200 | University of Mississippi Medical Center|Novartis Pharmaceuticals | Asthma | 2004-11 | NA |
| NCT01723072 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria|Angioedema | 2013-01-23 | PHASE3 |
| NCT04774315 | University of Colorado, Denver | Chronic Urticaria, Idiopathic | 2022-01-01 | PHASE4 |
| NCT05157087 | Novartis Pharmaceuticals | Asthma | 2020-03-01 | |
| NCT00232050 | Novartis|Daiichi Sankyo Co., Ltd. | Asthma | 2002-10 | PHASE3 |
| NCT05916937 | Simon Francis Thomsen|Aarhus University Hospital | Chronic Spontaneous Urticaria|Chronic Urticaria, Idiopathic | 2024-01-12 | PHASE4 |
| NCT06934200 | Johns Hopkins University|Genentech, Inc. | Food Hypersensitivity | 2025-05-19 | PHASE2 |
| NCT01580592 | Charite University, Berlin, Germany|Novartis Pharmaceuticals | Cold Contact Urticaria | 2012-04 | PHASE2 |
| NCT00434434 | Genentech, Inc. | Allergic Asthma | 2007-10 | PHASE2 |
| NCT02921178 | Ajou University School of Medicine | Asthma | 2016-09 | |
| NCT00377390 | National Institute of Allergy and Infectious Diseases (NIAID) | Asthma | 2006-10 | |
| NCT02023151 | Johns Hopkins University|Novartis Pharmaceuticals | Allergic Asthma | 2013-02 | PHASE4 |
| NCT00822783 | Medical University of Vienna | Atopic Dermatitis | 2001-10 | PHASE4 |
| NCT00472030 | University of Iowa|Genentech, Inc. | Bullous Pemphigoid | 2007-08 | PHASE4 |
| NCT00086606 | Genentech, Inc. | Allergy | 2004-06 | PHASE2 |
| NCT00219323 | Novartis|Daiichi Sankyo Co., Ltd. | Asthma | 2003-11 | PHASE3 |
| NCT00670930 | Novartis Pharmaceuticals|Genentech, Inc. | Allergic Asthma | 2008-04 | PHASE4 |
| NCT01922037 | Hoffmann-La Roche | Asthma | 2013-06-19 | PHASE4 |
| NCT01292473 | Genentech, Inc. | Chronic Idiopathic Urticaria | 2011-03 | PHASE3 |
| NCT04944602 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Chronic Spontaneous Urticaria | 2021-07 | PHASE3 |
| NCT05813470 | Cinnagen | Allergic Asthma|Uncontrolled Moderate to Severe | 2021-01-18 | PHASE3 |
| NCT02049294 | McMaster University|Novartis | Steroid and+or Prednisone Dependent Asthma|Eosinophilic Bronchitis | 2014-03 | PHASE2|PHASE3 |
| NCT00481676 | Novartis | Chronic Urticaria | 2007-05 | PHASE2 |
| NCT00482508 | Novartis|Genentech, Inc. | Asthma | 2003-05 | PHASE3 |
| NCT03280550 | Hoffmann-La Roche | Nasal Polyps|Chronic Rhinosinusitis | 2017-11-15 | PHASE3 |
| NCT05061524 | Yuhan Corporation | Atopic Healthy Subjects|Adult Subjects with Mild Allergic Diseases | 2021-09-26 | PHASE1 |
| NCT02118987 | Dana-Farber Cancer Institute|Novartis Pharmaceuticals | Drug Allergy | 2014-07 | PHASE1 |
| NCT00382148 | Genentech, Inc. | Peanut Hypersensitivity | 2006-11 | PHASE2 |
| NCT05564611 | Kashiv BioSciences, LLC | Healthy | 2022-11-04 | PHASE1 |
| NCT06316414 | Bambino Gesù Hospital and Research Institute | Food; Allergy, Anaphylactic Shock|Asthma in Children | 2018-01-01 | |
| NCT06103656 | New York Medical College|Icahn School of Medicine at Mount Sinai | Food Allergy | 2016-08-20 | PHASE2 |
| NCT03478930 | Hoffmann-La Roche | Nasal Polyps|Chronic Rhinosinusitis | 2018-05-09 | PHASE3 |
| NCT02262130 | Centre Hospitalier Universitaire de Besancon|Novartis | Solar Urticaria | 2014-09-30 | PHASE2 |
| NCT00287378 | University of North Carolina, Chapel Hill|National Institutes of Health (NIH)|Genentech, Inc. | Asthma|Allergy | 2006-03 | NA |
| NCT00482248 | Novartis|Genentech, Inc. | Asthma | 2003-06 | PHASE3 |
| NCT01544348 | MedImmune LLC | Allergic Asthma|Atopic Dermatitis|Allergic Rhinitis|Healthy Volunteers | 2012-01 | PHASE1 |
| NCT03580356 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 2018-10-20 | PHASE3 |
| NCT01912872 | Novartis Pharmaceuticals | Severe IgE-mediated Asthma | 2013-11-11 | PHASE4 |
| NCT05129033 | Shanghai Zhongshan Hospital | Allergic Bronchopulmonary Aspergillosis | 2021-11-15 | NA |
| NCT02388997 | University of Virginia|National Institute of Allergy and Infectious Diseases (NIAID) | Asthma | 2013-02-01 | PHASE2 |
| NCT04535817 | Beth Israel Deaconess Medical Center|Novartis | Autism Spectrum Disorder|Atopy | 2021-01-01 | PHASE1 |
| NCT01976208 | Shanghai Zhangjiang Biotechnology Limited Company | Allergic Asthma | 2010-12 | PHASE2|PHASE3 |
| NCT01393340 | University Hospital, Ghent|Novartis Pharma AG, Switzerland | Nasal Polyposis|Asthma | 2006-12 | PHASE2 |
| NCT06027073 | Medical University of Silesia|Centrum Medyczne Andrzej Bo?ek | Asthma, Allergic | 2024-05-01 | PHASE4 |
| NCT03328897 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 2017-04-26 | PHASE3 |
| NCT02402231 | Caroline Nilsson | Peanut Allergy | 2013-10 | PHASE2 |
| NCT00260702 | National Institute of Allergy and Infectious Diseases (NIAID) | Hyper-IgE Syndrome|Job´s Syndrome | 2005-11-24 | PHASE1 |
| NCT00133042 | University of Florida | Asthma | 2004-12 | PHASE4 |
| NCT00932282 | University of North Carolina, Chapel Hill|Genentech, Inc. | Peanut Hypersensitivity | 2009-07 | PHASE1|PHASE2 |
| NCT01716754 | Novartis Pharmaceuticals | Asthma | 2012-12 | PHASE2 |
| NCT00396409 | Novartis Pharmaceuticals | Allergic Asthma | 2006-02 | PHASE3 |
| NCT04489121 | Beijing Tongren Hospital | Seasonal Allergic Rhinitis | 2020-07-28 | NA |
| NCT00314574 | Genentech, Inc. | Asthma | 2005-12 | PHASE3 |
| NCT02169115 | Charite University, Berlin, Germany|Novartis Pharmaceuticals | Symptomatic Dermographism | 2012-12 | PHASE2 |
| NCT04045301 | Philippe Bégin|The Hospital for Sick Children|Centre hospitalier de l´Université de Montréal (CHUM)|Centre de recherche du Centre hospitalier universitaire de Sherbrooke | Food IgE-mediated Allergy|Immunotherapy|Omalizumab|Physiological Effects of Drugs | 2019-11-11 | PHASE2 |
| NCT03476109 | Cliniques universitaires Saint-Luc- Université Catholique de Louvain|University Hospital, Ghent|University of Liege|CHU de Charleroi|Erasme University Hospital|Centre Hospitalier Universitaire UCLouvain Namur|Universitair Ziekenhuis Brussel|Brugmann University Hospital|Grand H?pital de Charleroi|AZ Delta|Centre Hospitalier Universitaire Saint Pierre|KU Leuven | Severe Asthma | 2019-05-10 | PHASE4 |
| NCT04833855 | Amgen | Chronic Spontaneous Urticaria | 2021-04-15 | PHASE2 |
| NCT00046748 | Novartis Pharmaceuticals | Asthma | 2001-12 | PHASE3 |
| NCT06509334 | Jemincare | Chronic Spontaneous Urticaria | 2024-08-04 | PHASE2 |
| NCT01040598 | O & O Alpan LLC|Genentech, Inc. | Eosinophilic Esophagitis | 2009-06 | PHASE1 |
| NCT01678092 | Stanford University | Atopic Dermatitis | 2004-05 | PHASE1 |
| NCT03369704 | Novartis Pharmaceuticals | Seasonal Allergic Rhinitis | 2017-12-15 | PHASE3 |
| NCT03111628 | Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID) | Urticaria Chronic | 2017-10-06 | PHASE4 |
| NCT00109200 | Genentech, Inc. | Asthma | 2003-05 | PHASE3 |
| NCT00079937 | Novartis Pharmaceuticals | Asthma | 2004-04 | PHASE3 |
| NCT02968394 | The University Clinic of Pulmonary and Allergic Diseases Golnik | Allergy|Bee Venom|Immunotherapy|Omalizumab | 2014-03 | NA |
| NCT01703312 | Novartis Pharmaceuticals | Allergic Asthma | 2012-11 | PHASE1|PHASE2 |
| NCT01264939 | Genentech, Inc. | Chronic Idiopathic Urticaria | 2011-02 | PHASE3 |
| NCT01202903 | Novartis Pharmaceuticals|Genentech, Inc. | Persistent Allergic Asthma | 2010-09 | PHASE3 |
| NCT02742805 | Selina Gierer, D.O. | Urticaria | 2016-02 | PHASE4 |
| NCT01003301 | Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|Genentech, Inc. | Cat Allergy | 2009-10 | PHASE2 |
| NCT06618963 | National Jewish Health|Roche-Genentech | Food Allergy|Food Allergy in Children | 2024-10-01 | PHASE4 |
| NCT04128176 | University of California, Davis | Bullous Pemphigoid | 2017-03 | PHASE3 |
| NCT04601389 | AO GENERIUM | Healthy Volunteers | 2017-04-18 | PHASE1 |
| NCT01157117 | Hugh A Sampson, MD|National Institute of Allergy and Infectious Diseases (NIAID) | Milk Allergy | 2010-08 | PHASE2 |
| NCT00567476 | Novartis | Asthma | 2007-11 | PHASE4 |
| NCT00657891 | Creighton University|Novartis Pharmaceuticals | Asthma | 2007-03 | PHASE4 |
| NCT03964051 | Carsten Bindslev-Jensen|Miltenyi Biomedicine GmbH | Food Allergy | 2019-07-01 | PHASE4 |
| NCT05774639 | Kashiv BioSciences, LLC|COD Research Private Ltd | Chronic Idiopathic Urticaria | 2023-08-15 | PHASE3 |
| NCT00968110 | Boston Children´s Hospital|Stanford University | Milk Allergy | 2009-03 | EARLY_PHASE1 |
| NCT01007149 | Novartis Pharmaceuticals | Asthma | 2009-09 | PHASE3 |
| NCT05424523 | Novartis Pharmaceuticals | Allergic Asthma | 2021-02-25 | |
| NCT00109187 | Genentech, Inc. | Asthma | 2002-06 | PHASE3 |
| NCT02161562 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 2014-08-01 | PHASE3 |
| NCT00078195 | National Institute of Allergy and Infectious Diseases (NIAID)|Immune Tolerance Network (ITN) | Hay Fever|Hypersensitivity|Allergy|Rhinitis | 2003-04 | PHASE2 |
| NCT04720612 | McGill University Health Centre+Research Institute of the McGill University Health Centre | Covid19 | 2021-10-15 | PHASE2 |
| NCT05390255 | Beijing Tongren Hospital|Peking Union Medical College Hospital|Beijing Hospital | Sinusitis | 2022-05-25 | PHASE3 |
| NCT00096954 | Genentech, Inc. | Asthma | 2006-02 | PHASE4 |
| NCT00639691 | Novartis | Asthma | 2005-01 | PHASE4 |
| NCT06806826 | Yuzuncu Yil University | Allergic Rhinitis | 2019-01-01 | PHASE4 |
| NCT01713725 | Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinic of Barcelona|Hospital Universitario Central de Asturias|Gregorio Mara?ón Hospital|Hospital Universitari Joan XXIII de Tarragona.|Complejo Hospitalario de Navarra|Hospital Vall d´Hebron|Hospital Clínico Universitario Lozano Blesa | Chronic Urticaria | 2012-03 | PHASE2 |
| NCT05564221 | Yuhan Corporation | Atopic Healthy Subjects|Adult Subjects With Allergic Diseases | 2022-11-01 | PHASE1 |
| NCT00555971 | David Lang|Genentech, Inc. | Aspirin Sensitivity | 2006-05 | PHASE4 |
| NCT06437171 | AAADRS Clinical Research Center | Food Allergy | 2024-06-03 | PHASE4 |
| NCT03181009 | Andrew Long, PharmD|University of California, Los Angeles | Food Allergy | 2017-07-31 | PHASE2 |
| NCT00123630 | University of Utah|Novartis Pharmaceuticals | Esophagitis | 2005-11 | PHASE2 |
| NCT00208234 | Creighton University|Genentech, Inc. | Allergic Asthma | 2004-01 | PHASE4 |
| NCT04998604 | Sanofi|Regeneron Pharmaceuticals | Chronic Rhinosinusitis With Nasal Polyps|Asthma | 2021-09-27 | PHASE4 |
| NCT04158050 | Helsinki University Central Hospital|Ida Montini Foundation | Asthma | 2018-01-01 | |
| NCT07342803 | Longbio Pharma | Allergic Asthma | 2025-01-25 | PHASE2 |
| NCT02626611 | Kari Christine Nadeau|Icahn School of Medicine at Mount Sinai|Children´s Hospital of Philadelphia|Ann & Robert H Lurie Children´s Hospital of Chicago|Children´s Hospital Medical Center, Cincinnati|Children´s Hospital Los Angeles|University of Washington | Food Allergy | 2015-12 | PHASE2 |
| NCT01701583 | University of Colorado, Denver|Genentech, Inc. | Chronic Urticaria | 2013-04 | PHASE4 |
| NCT01155700 | Novartis Pharmaceuticals | Allergic Asthma | 2010-06 | PHASE3 |
| NCT04195958 | Genentech, Inc. | Moderate-to-severe Allergic Asthma | 2020-11-30 | PHASE4 |
| NCT04037176 | Carsten Bindslev-Jensen|Novartis Pharmaceuticals|Thermo Fisher Scientific, Inc | Food Allergy | 2019-11-01 | PHASE4 |
| NCT07059091 | Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID)|Genentech, Inc.|American Lung Association Asthma Clinical Research Centers|American Lung Association | Chronic Obstructive Pulmonary Disease (COPD)|Allergies | 2026-02-12 | PHASE2 |
| NCT00242359 | Bernstein Clinical Research Center | Allergy Induced Asthma | 2005-11 | PHASE4 |
| NCT01510626 | Stanford University | Immune System Diseases | 2011-11 | PHASE1 |
| NCT03679676 | Stanford University|National Institute of Allergy and Infectious Diseases (NIAID)|Food Allergy Research & Education|Harvard School of Public Health (HSPH) | Hypersensitivity|Food Allergy|Hypersensitivity, Food|Peanut Hypersensitivity|Peanut Allergy | 2020-02-05 | PHASE2 |
| NCT07073404 | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|Institute of Biomedical Research in Málaga (IBIMA) | Food Allergies | 2026-01 | |
| NCT03881696 | National Institute of Allergy and Infectious Diseases (NIAID)|Genentech, Inc.|Novartis Pharmaceuticals|Rho Federal Systems Division, Inc. | Peanut Allergy|Multi-food Allergy | 2019-07-22 | PHASE3 |
| NCT01290913 | Lynda Schneider | Peanut Allergy | 2011-02 | PHASE1|PHASE2 |
| NCT03280537 | Hoffmann-La Roche | Nasal Polyps|Chronic Rhinosinusitis | 2017-11-21 | PHASE3 |
| NCT02654145 | GlaxoSmithKline | Asthma | 2016-03-17 | PHASE4 |
| NCT06438757 | Jemincare | Allergic Asthma | 2024-06-19 | PHASE2 |
| NCT04361812 | BioRay Pharmaceutical Co., Ltd. | Similarity of Pharmacokinetics and Safety | 2020-10-15 | PHASE1 |
| NCT00851370 | National Jewish Health|Novartis | Pulmonary Disease, Chronic Obstructive | 2009-01 | PHASE2 |
| NCT00084097 | National Institute of Allergy and Infectious Diseases (NIAID) | Gastroenteritis | 2004-06-02 | PHASE2 |
| NCT01584687 | Instituto de Investiga??o em Imunologia | Asthma | 2012-06 | PHASE4 |
| NCT00870584 | Novartis Pharmaceuticals|Genentech, Inc. | Persistent Allergic Asthma | 2009-03 | PHASE4 |
| NCT01803763 | Insel Gruppe AG, University Hospital Bern|Adverse Drug Reactions, Advice and Consulting ADR-AC|University of Bern|Novartis | Chronic Urticaria|Chronic Idiopathic Urticaria|Chronic Spontaneous Urticaria | 2012-09 | PHASE2|PHASE3 |
| NCT06683261 | Universitaire Ziekenhuizen KU Leuven | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)|Chronic Rhinosinusitis (CRS) | 2022-09-23 | |
| NCT00454051 | Novartis Pharmaceuticals | Asthma | 2006-12 | PHASE4 |
| NCT07425639 | Celltrion HealthCare France | Chronic Spontaneous Urticaria (CSU)|Allergic Asthma | 2025-10-02 | |
| NCT06042478 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 2023-11-15 | PHASE3 |
| NCT04583501 | Johns Hopkins University|Genentech, Inc. | Chronic Rhinosinusitis With Nasal Polyps|Nasal Polyps | 2020-12-15 | EARLY_PHASE1 |
| NCT00500539 | Novartis|Genentech, Inc.|Tanox | Asthma | 2007-07 | PHASE3 |
| NCT00495612 | Genentech, Inc. | Asthma | 2007-09 | PHASE4 |
| NCT05449535 | Jemincare | Healthy | 2022-05-07 | PHASE1 |
| NCT00130234 | Johns Hopkins University|Genentech, Inc. | Urticaria | 2004-11 | PHASE2 |
| NCT01066104 | Massachusetts General Hospital|Genentech, Inc. | Chronic Rhinosinusitis|Nasal Polyps | 2009-12 | PHASE2 |
| NCT01125748 | Genentech, Inc. | Allergic Asthma | 2010-05 | PHASE4 |
| NCT00787917 | Novartis Pharmaceuticals | Cystic Fibrosis|Allergic Bronchopulmonary Aspergillosis | 2008-11 | PHASE4 |
| NCT01287117 | Genentech, Inc. | Chronic Idiopathic Urticaria | 2011-02 | PHASE3 |
| NCT05332067 | Children´s National Research Institute|National Institute of Allergy and Infectious Diseases (NIAID) | Asthma in Children|Atopy|Viral Upper Respiratory Infection | 2022-05-01 | PHASE2 |
| NCT07246252 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Healthy Volunteers (HV) | 2024-03-28 | PHASE1 |
| NCT00264849 | Novartis|Genentech, Inc.|Tanox | Asthma | 2005-11 | PHASE4 |
| NCT02879006 | Xiu-Min Li | Food Allergy | 2016-08 | PHASE2 |
| NCT00604786 | Johns Hopkins University|National Institute of Allergy and Infectious Diseases (NIAID) | Allergic Rhinitis | 2007-07 | NA |
| NCT01328886 | Novartis Pharmaceuticals | Allergic Asthma | 2011-03 | PHASE3 |
| NCT00401596 | Genentech, Inc. | Asthma | 2000-07 | PHASE3 |
| NCT07356713 | Excellergy Inc. | Allergic Disease | 2026-01-08 | PHASE1 |
| NCT02266355 | Yale University | Colon Cancer | 2014-11 | PHASE1 |
| NCT02658877 | NYU Langone Health | Asthma | 2016-01 | PHASE4 |
| NCT00546143 | Novartis | Asthma | 2007-07 | PHASE4 |
| NCT06771934 | Qianfoshan Hospital | Allergic Asthma | 2024-06-01 | |
| NCT00162773 | Johns Hopkins University|Genentech, Inc. | Asthma | 2005-04 | PHASE2 |
| NCT05960708 | Yuhan Corporation | Allergic Disease|Chronic Spontaneous Urticaria|Chronic Inducible Urticaria|Cold Urticaria | 2023-08-23 | PHASE1 |
| NCT05405478 | Shiraz University of Medical Sciences | Nasal Polyps | 2022-06-01 | PHASE4 |
| NCT00367016 | University of California, Davis | Asthma|Allergic Rhinitis|Atopic Dermatitis | 2004-02 | PHASE4 |
| NCT03727971 | Rigshospitalet, Denmark|Novartis|Hvidovre University Hospital|Herlev Hospital|Zealand University Hospital | Asthma|Infertility, Female | 2019-01-01 | PHASE2 |
| NCT06943534 | Massachusetts General Hospital | Allergies|Food Allergy | 2025-07-03 | PHASE2 |
| NCT03580369 | Novartis Pharmaceuticals | Chronic Spontaneous Urticaria | 2018-10-17 | PHASE3 |
| NCT02392624 | Genentech, Inc. | Urticaria | 2015-05-18 | PHASE4 |
| NCT00866788 | Genentech, Inc. | Chronic Idiopathic Urticaria | 2009-03 | PHASE2 |
| NCT00890162 | National Institute of Allergy and Infectious Diseases (NIAID) | Anaphylaxis|Hypotension|Bronchospasm|Angioedema | 2009-04-27 | PHASE2 |
| NCT04665141 | Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinic of Barcelona|Hospital Regional de Malaga | Asthma | 2021-04-07 | |
| NCT01113437 | King´s College London | Bronchial Asthma | 2010-04 | PHASE2|PHASE3 |
| NCT00286416 | Scripps Clinic | Asthma|Allergic Rhinitis | 2006-01 | NA |
| NCT02550106 | Novartis Pharmaceuticals | CHRONIC SPONTANEOUS URTICARIA | 2015-04-22 | PHASE4 |
| NCT01893658 | Mayo Clinic|Genentech, Inc. | Acute Interstitial Nephritis | 2018-06-01 | PHASE2 |
| NCT04778137 | Taizhou Mabtech Pharmaceutical Co.,Ltd | Asthma | 2020-12-01 | PHASE1 |
| NCT00117611 | University of Chicago|Genentech, Inc.|Novartis Pharmaceuticals | Sinusitis | 2005-07 | PHASE4 |
| NCT00829179 | Duke University|Genentech, Inc. | Allergic Asthma | 2002-10 | PHASE3 |